Presentation is loading. Please wait.

Presentation is loading. Please wait.

Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF  Laura P. Stabile, PhD, Mary.

Published byNathaniel Harrington Modified over 6 years ago

Similar presentations

Presentation on theme: "Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF  Laura P. Stabile, PhD, Mary."— Presentation transcript:

1 Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF  Laura P. Stabile, PhD, Mary E. Rothstein, BS, Christopher T. Gubish, MS, Diana E. Cunningham, MS, Nathan Lee, Jill M. Siegfried, PhD  Journal of Thoracic Oncology  Volume 9, Issue 9, Pages (September 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Proliferation and invasion with single and combination treatments of celecoxib and crizotinib. A, 201T and 273T lung cancer cells were treated with celecoxib or crizotinib alone or in combination using the concentrations that inhibit 50% (IC50) of each drug for 72 hours. Relative cell proliferation was determined with each treatment. Control was set to 100. The results show significant differences between the combination treatment and each single agent and the control. Maximum decreases were observed with combination treatment. Similar results were obtained with the IC50 and IC25 conditions. ***p < 0.001, analysis of variance (ANOVA). B, 201T and 273T lung cancer cells were plated on Matrigel invasion chambers and were treated with celecoxib or crizotinib alone or in combination using the IC50 concentrations of each drug for 24 hours. Cells were fixed, stained, and counted for the number of invading cells. The combination treatment maximally inhibited cellular invasion in both cell lines. *p < 0.05; **p < 0.005; ***p < 0.001, ANOVA. n.s., Nonsignificant. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Representative cyclooxygenase-2 (COX-2) staining in lungs of hepatocyte growth factor transgenic (HGF TG) mice with and without NNK treatment. A, Control aged-matched lungs from HGF TG animals and (C) wild-type animals with no NNK treatment. B, HGF TG and (D) wild-type mouse lungs after animals were treated with 6-mg NNK and preneoplastic lesions were allowed to form for 10 weeks. These lesions are analogous to human atypical adenomatous hyperplasia. Lungs were formalin inflated and stained for COX-2 by immunohistochemistry. Representative images are shown. Red arrows represent COX-2-positive infiltrating leukocytes. Black arrows represent area of high-powered magnification. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Boxplot of the number of tumors per mouse by treatment group analyzed by Poisson regression analysis. B, Boxplot of the log (tumor size mm2) by treatment group. A mixed effects model was used for analysis of tumor size. Horizontal line in box of boxplots represents the median. +, the mean; ; ns, nonsignificant. **p < 0.001; *p < 0.01. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Biomarkers modulated by treatment. P-c-Met, prostaglandin E2 (PGE2), cyclooxygenase-2 (COX-2), and P-MAPK expression was examined by immunohistochemistry in tumors arising from different treatment groups. Lungs were fixed in 10% buffered formalin. Lung samples were paraffin embedded, sliced, and mounted on slides. Representative staining for each marker and treatment group is shown. Quantitation was performed from three to five tumors per treatment group on a 1 to 4 scaling system, and determining the mean score. 1 = 1–25% positivity, 2 = 26–50% positivity, 3 = 51–75% positivity, and 4 76–100% positivity. Scale bar= 100 μm. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 EMT was modulated by single and dual treatment. Expression of E-cadherin and Snail was examined using immunohistochemistry in tumors arising from different treatment groups. Representative staining for each marker and treatment group is shown. Quantitation was performed from three to five high-powered tumor fields per area by counting the number of positive cells per field. ***p < 0.001; *p < Scale bar = 50 μm. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF  Laura P. Stabile, PhD, Mary."

Similar presentations

Volume 16, Issue 12, Pages (December 2014)

Volume 16, Issue 12, Pages (December 2014)
Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts  Min Yao, Curtis Smart, Qingting.

Continuous Delivery of Neutralizing Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts  Min Yao, Curtis Smart, Qingting.
Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
Volume 22, Issue 6, Pages (December 2012)

Volume 22, Issue 6, Pages (December 2012)
Figure S1 a b c d DAPI Lgr β-catenin Merge

Figure S1 a b c d DAPI Lgr β-catenin Merge
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,

DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma  Sun Hye Kim, Man Li, Sebastian.

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma  Sun Hye Kim, Man Li, Sebastian.
Volume 18, Issue 8, Pages (February 2017)

Volume 18, Issue 8, Pages (February 2017)
Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non– small cell lung cancer  Leah M. Backhus, MD, Nicos A. Petasis, PhD,

Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non– small cell lung cancer  Leah M. Backhus, MD, Nicos A. Petasis, PhD,
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Chandra M.V. Goparaju, PhD  Journal of Thoracic Oncology 

Chandra M.V. Goparaju, PhD  Journal of Thoracic Oncology 
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21

Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas
Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage- Dominant Microenvironment in Lung Cancer  Lunxu Liu, MD, PhD, Dongxia.

Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage- Dominant Microenvironment in Lung Cancer  Lunxu Liu, MD, PhD, Dongxia.
The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death  Kwang Woon Kim, PhD, Christina K. Speirs,

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death  Kwang Woon Kim, PhD, Christina K. Speirs,
Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)  Koji Kurose, MD, Yoshihiro.

Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)  Koji Kurose, MD, Yoshihiro.

Similar presentations

Ads by Google